BioNTech Results Presentation Deck

BNT162: Global development program expanded to additional regions Phase 2/3¹ 8 Regulatory submissions on a rolling basis Ongoing trials Phase 2/3¹ ¹Phase 1/2 remains ongoing in U.S. and EU Phase 2/3 Phase 2/3 Phase 2/3 Phase 2/3 Phase 1/2 Phase 1 Regulatory submission on a rolling basis to EMA, MHRA (UK) and Health Canada initiated in October BIONTECH

View entire presentation